Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01191216 · ClinicalTrials.gov registry record · Phase 1

1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors

A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
27
Enrollment target
5
Study locations

NCT01191216 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 27 participants, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01191216, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target
5
Study locations

Study Summary

This phase I trial is studying the side effects and best dose of giving 1-methyl-d-tryptophan and docetaxel together in treating patients with metastatic solid tumors. Biological therapies, such as 1-methyl-d-tryptophan, may stop the growth of tumor cells by stimulating the immune system and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving 1-methyl-d-tryptophan with chemotherapy may kill more tumor cells.

Conditions Studied

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

  • DRUG docetaxel
  • OTHER pharmacological study
  • OTHER diagnostic laboratory biomarker analysis
  • DRUG 1-methyl-d-tryptophan

Study Locations (5)

Florida

  • H. Lee Moffitt Cancer Center and Research Institute - Tampa

Georgia

  • Emory University/Winship Cancer Institute - Atlanta

Montana

  • Billings Clinic - Billings

North Carolina

  • University of North Carolina - Chapel Hill

Virginia

  • Virginia Commonwealth University - Richmond

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2010-09
Est. Completion 2013-08
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01191216

The ClinicalTrials.gov registry entry for NCT01191216 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (95% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 4 interventions - of which docetaxel is the first listed.

NCT01191216 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, Georgia, Montana.

Frequently Asked Questions

What is clinical trial NCT01191216 about?

NCT01191216 is a clinical study titled "1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors". This phase I trial is studying the side effects and best dose of giving 1-methyl-d-tryptophan and docetaxel together in treating patients with metastatic solid tumors. Biological therapies, such as 1-methyl-d-tryptophan, may stop the growth of tumor cells by stimulating the immune system and by bloc...

What is the current status of trial NCT01191216?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2010-09. Estimated completion is 2013-08.

What conditions does trial NCT01191216 study?

This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.

What interventions are being tested in trial NCT01191216?

The interventions under investigation include: docetaxel (DRUG), pharmacological study (OTHER), diagnostic laboratory biomarker analysis (OTHER), 1-methyl-d-tryptophan (DRUG).

Who is sponsoring clinical trial NCT01191216?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01191216 being conducted?

This trial has 5 study locations across Florida, Georgia, Montana, North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Unspecified Adult Solid Tumor, Protocol Specific

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Unspecified Adult Solid Tumor, Protocol Specific

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.